Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pending regulations promote pre-emption

This article was originally published in The Tan Sheet

Executive Summary

FDA inserts pre-emption language into seven finalized proposed rules, the American Association for Justice reports in a list of the pending rules. In a report critical of the Bush administration's inclusion of such language in agency-wide regulations, AAJ says pre-emption provides a "get out of jail free" card to companies. FDA first mandated pre-emption in the 2006 physician labeling rule. Similar language is in proposed rules on pregnancy and lactation labeling, skin bleaching drug products, OTC drug labeling, OTC analgesics, labeling on calcium claims, sunscreen labels and a proposed fatty acid rule (1"The Tan Sheet" June 9, 2008, In Brief). FDA proposed three of the rules in 2006 and three in 2007. They go into effect 60 days before President Bush leaves office

You may also be interested in...



Rx label changes affect OTC use?

FDA's proposal to update the format of the pregnancy and lactation sections of drug labeling may encourage women to use "safe and effective products," including Rx drugs that "they might otherwise avoid" because of safety concerns, the agency says. The rule published in the May 29 Federal Register would require labels to include "up-to-date information on the risks and benefits of prescription drugs" on pregnant women, their fetuses and lactation. FDA cites studies that found pregnant women often take OTC drugs and dietary supplements instead of prescription products because they perceive those products are safer, even though safety information on OTC products and supplements "is as limited, if available at all, as that for prescription drugs"...

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel